Latest news

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead’s…

Lancement de la 10e édition du Challenge Qualité de Vie du Patient

Genialis advances biomarker discovery to reduce risk in cancer drug development targeting DNA damage response pathways

Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea

Vulgaroo remporte le 9e Challenge qualité de vie du patient avec un prix de 25’000 francs suisse

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Debiopharm to Showcase Research Results of Their First-In-Class Anti-Staphylococcal Program at IDWeek 2024 in Los Angeles

Debiopharm Recognizes Groundbreaking Japanese Cancer Research During the 83rd Annual Meeting of the Japanese Cancer Association

Debiopharm and WhiteLab Genomics announce a collaboration to advance drug target and design in Oncology